{
    "nctId": "NCT03481894",
    "officialTitle": "Prospective, Randomized, Open-Label, Parallel-Group, Active-Controlled, Multicenter Study to Assess Safe and Effective Doses of Kabiven\u00ae in Pediatric Patients 2 to 16 Years of Age",
    "inclusionCriteria": "* Male or female patients 2 to 16 years of age\n* Patients who require at least 80% of their caloric intake as PN at study start, and in whom an indication for PN is expected for at least 5 days\n* Patients who require a central venous line to receive PN or already have a central venous line in place for other reasons\n* Written informed consent from legal representative(s)\n* Must have minimum age of 2 Years\n* Must have maximum age of 16 Years",
    "exclusionCriteria": "* Known hypersensitivity to egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients\n* Severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration \\>1,000 g/dL).\n* Inborn errors of amino acid metabolism\n* Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support)\n* Hemophagocytic syndrome.\n* PN in the last 7 days prior to study enrollment.\n* Need for chronic PN before study start\n* Liver enzymes (either AST, ALT, GGPT), or direct bilirubin exceeding 2 x upper limit of normal range\n* Pathologically altered level of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate) unless corrected prior to the start of study treatment\n* Pathologically altered blood pH, or oxygen saturation, or carbon dioxide unless corrected prior to the start of study treatment\n* Pregnancy or lactation\n* Participation in another clinical study"
}